(Technical principle)

• The preparation of hybridoma-HVJ-E cell fusion reagent promotes cell membrane fusion by binding its envelope protein with the host cell membrane, resulting in the formation of hybridoma cells with the ability to produce monoclonal antibodies and unlimited proliferation potential.

• It is applied in development, reproduction, and breeding research, such as nuclear transfer in enucleated unfertilized eggs—primarily by promoting the fusion of the fertilized egg with the membrane of the cell providing the nucleus through its envelope protein, allowing the recipient egg cell to accept the donor cell's nucleus, thereby achieving nuclear transfer and subsequent embryo development and species reproduction.

• Spindle Transfer: These reagents facilitate spindle transfer procedures, a technique commonly used in reproductive biology to transfer the spindle apparatus between oocytes, supporting successful cell fusion and genetic manipulation. (The recommended soaking time in spindle transplantation experiments should not exceed 5 seconds.)

• Oncolytic Virotherapy: In cancer treatment, cell fusion reagents assist in the development of oncolytic viruses, which selectively target and destroy cancer cells, representing a promising therapeutic approach.（Mast cell tumors, MCTs) 
• VLP（Gene Delivery Vector): Plasmids, decoy nucleic acids (DNA), and small interfering RNA (siRNA), as well as messenger RNA (mRNA), are macromolecules that require a delivery system called a "vector" to be efficiently introduced into target tissues or cells. HVJ-envelope (HVJ-E) uses the virus’s membrane fusion mechanism, allowing for the active delivery of DNA or RNA into target cells in a manner similar to injection. Unlike passive uptake via phagocytosis, this method involves the vector itself fusing with the cell membrane, offering a more efficient delivery. While utilizing the virus’s membrane fusion mechanism, HVJ-E does not use the viral genome, making it a non-viral hybrid vector. Initially developed for gene and nucleic acid delivery, it has now progressed to clinical trials as a therapeutic for cancer and infectious diseases, attracting attention as a novel gene nucleic acid delivery vector. 

Related application literature of HVJ-E:

“All in one” lipid-polymer nanodelivery system for gene therapy of ischemic diseases